MagPortal.com   Clustify - document clustering
 Home  |  Newsletter  |  My Articles  |  My Account  |  Help 
Similar Articles
The Motley Fool
July 8, 2011
One Biotech Stock to Avoid Our investing community's latest stock to avoid is Zalicus, which in five years has never completed development of any drug or even initiated a phase III trial. mark for My Articles similar articles
The Motley Fool
August 15, 2011
Jim Royal
6 Wild Bets on Biotech Riches The most interesting biotech tickers. mark for My Articles similar articles
The Motley Fool
March 12, 2009
Rich Smith
This Just In: Upgrades and Downgrades Even after acknowledging that all of Motorola's businesses are facing strong headwinds that will get stronger in '09, analyst Oppenheimer nonetheless chose to upgrade Motorola shares to "outperform." mark for My Articles similar articles
The Motley Fool
November 9, 2011
David Williamson
Market Crash = Biotech Carnage Highlighting the day's health-care stories critical to investors. mark for My Articles similar articles